Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL17801917 | 0.99 | KDM4E (0.37) | KDM4EACACBACACAKMT2ACACNA1H | |
| SCHEMBL19342748 | 0.80 | KDM4E (0.44) | KDM4EACACBACACAKMT2ACACNA1H | |
| SCHEMBL1918148 | 0.77 | EGLN1 (0.40) | KDM4EACACBACACAKMT2ACACNA1H | |
| SCHEMBL6456171 | 0.75 | ADORA3 (0.46) | KDM4EKMT2AADORA3ADORA2AADORA1 | |
| SCHEMBL3640946 | 0.75 | ACACB (0.36) | KDM4EACACBACACAKMT2ACACNA1H | |
| SCHEMBL4553606 | 0.73 | ACACB (0.36) | KDM4EACACBACACAKMT2ACACNA1H | |
| SCHEMBL9754820 | 0.73 | KMT2A (0.37) | KDM4EACACBACACAKMT2APOLB | |
| SCHEMBL3712698 | 0.73 | KMT2A (0.38) | KDM4EACACBACACAKMT2ACACNA1H | |
| SCHEMBL158112 | 0.72 | ACACB (0.45) | KDM4EACACBACACAKMT2APRKCZ | |
| SCHEMBL14855819 | 0.72 | KMT2A (0.35) | KDM4EACACBACACAKMT2ACACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077242-B2 | Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-09-18 | — | — | US | disclosed |
| US-20170260146-A1 | A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-09-14 | — | — | US | disclosed |
| WO-2016089845-A1 | A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077242-B2 | Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction | AGTR2, AGTR1, REN | KDM4E 2667/4885ACACB 2198/4885ACACA 2595/4885 |
| US-20170260146-A1 | A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION | REN, AGTR1, AGTR2 | KDM4E 2894/4885ACACB 2633/4885ACACA 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.